Previous 10 | Next 10 |
home / stock / cslly / cslly news
CSL Pharma, a division of CSL Limited (CSLLY), will not renew a supply agreement with Haemonetics (HAE) for the use PCS2 Plasma Collection System devices and the purchase of plasmapheresis kits.The agreement expires in June 2022 and accounted for $117M -- 11.8% -- of overall ...
Seqirus Publishes New Real-World Evidence Supporting the Effectiveness of Adjuvanted Seasonal Influenza Vaccine in Adults 65 Years and Older in Clinical Infectious Diseases PR Newswire SUMMIT, N.J. , April 20, 2021 /PRNewswire/ -- Seqirus, a global leader in infl...
Terumo Blood and Cell Technologies and CSL Plasma Announce Collaboration to Deliver New Plasma Collection Platform Plasma is key ingredient for therapies crucial to treating patients affected by life-threatening conditions PR Newswire LAKEWOOD, Colo. and BO...
Project $1M, my long-term growth portfolio designed to deliver $1M in 10 years, had a very tough Q1. The portfolio was caught in the shift in market sentiment from growth to value. Facebook and Alphabet performed relatively well, while ARK Genomic, MercadoLibre, and Teladoc suffer...
New Seqirus Data Published in Vaccines Highlight Effectiveness and Economic Benefit of Cell-Based Quadrivalent Seasonal Influenza Vaccine (QIVc) in the 2018/19 U.S. Influenza Season PR Newswire SUMMIT, N.J. , March 25, 2021 /PRNewswire/ -- Seqirus, a global ...
Seqirus, a unit of CSL Limited ([[CSLLY]] -2.2%) has announced that Health Canada has approved FLUCELVAX QUADRIVALENT (Influenza Vaccine) for people two years of age and older.Previously, Health Canada authorized the cell-based quadrivalent influenza vaccine for use in persons nine ...
Seqirus, a unit of CSL Limited (CSLLY) has received the FDA approval for Flucelvax Quadrivalent (Influenza Vaccine) for an expanded age indication for people aged two years and older."Young children are at a high risk of complications from influenza, which is why annual vaccination ...
Seqirus Announces U.S. FDA Approval of Expanded Age Indication of Its Cell-Based Quadrivalent Influenza Vaccine for People Two Years of Age and Older PR Newswire SUMMIT, N.J. , March 5, 2021 /PRNewswire/ -- Seqirus, a global leader in influenza prevention, t...
The Project $1M portfolio stumbled against the S&P 500 in February. In spite of February's decline, the portfolio still remains well up on the S&P 500 over five years. Teladoc and MercadoLibre were laggards, while Mastercard delivered well last month. As yields rise an...
The National Institutes of Health has halted a clinical trial evaluating the safety and effectiveness of COVID-19 convalescent plasma in emergency room patients with mild to moderate symptoms of COVID-19.Following a second planned interim analysis of the trial data, an independent d...
News, Short Squeeze, Breakout and More Instantly...
CSL Ltd ADR Company Name:
CSLLY Stock Symbol:
OTCMKTS Market:
CSL Behring Announces Positive Reimbursement Decision in Canada for HEMGENIX® (etranacogene dezaparvovec), the First Gene Therapy for Hemophilia B Canada NewsWire The positive decision from the Canadian Agency for Drugs and Technologies in Health (CADTH) recognizes the im...
CSL Seqirus Begins Shipping Its Portfolio of Influenza Vaccines for the 2024/25 Flu Season PR Newswire CSL Seqirus is the only manufacturer to offer a differentiated influenza vaccine for all eligible people aged six months and older in the United States . Centers for ...
CSL Seqirus, a Proud Champion of Pandemic Preparedness, Announces U.S. Government Award in Response to Avian Influenza PR Newswire CSL Seqirus to complete the fill and finish process for pre-pandemic vaccine to support the U.S. government's outbreak and preparedness response...